Varian Introduces Isolis Cryoprobe to Simplify Planning and Guidance During Cryoablation Procedures

Varian, a Siemens Healthineers company, is introducing the Isolis™ cryoprobe, a single use, disposable device designed for use with CryoCare® systems* that seeks to improve procedural efficiency and precision for cryoablation. Cryoablation is a minimally invasive, image-guided procedure for treating disease and alleviating pain by very precisely freezing and destroying tissue targets such as tumors of the lung, liver, breast, kidney, prostate, and soft tissue.

The new Isolis cryoprobe offers the interventional radiologist greater operational control, with features designed to enhance predictability, precision, and efficiency.  It features a small 2.1mm/14-gauge shaft and a sharp probe tip to facilitate smooth and accurate placement.

Isolis is also the first cryoprobe to offer optional integration with the Siemens Healthineers myNeedle Laser** guidance system, which was developed for image-guided interventional procedures. The clinician can use myNeedle Laser to guide the insertion and trajectory of the cryoprobe while using imaging to monitor placement progress.

“The Isolis cryoprobe reflects the significant opportunity Varian has as a Siemens Healthineers company to seek to raise the standards of procedural efficiency and precision,” said Francis (Frank) Facchini, MD, President, Interventional Solutions at Varian.  “This exciting development represents the first new interventional radiology product since combining with Siemens Healthineers, and a first step towards our goal of making these impactful, minimally invasive treatment options easier to execute and more widely accessible to the patients who can benefit. We look forward to further collaboration and innovation on behalf of patients worldwide, as we continue to advance our mission to help create a world without fear of cancer.”

The products/features (mentioned herein) are not commercially available in all countries. Their future availability cannot be guaranteed.

*CryoCare systems are intended for use in open, minimally invasive or endoscopic surgical procedures in the areas of general surgery, urology, gynecology, oncology, neurology, dermatology, ENT, proctology, pulmonary surgery, and thoracic surgery. The systems are designed to freeze/ablate tissue by the application of extreme cold temperatures, including prostate and kidney tissue, liver metastases, tumors, skin lesions, and warts.

**myNeedle™ and myNeedle Laser are trademarks of Siemens Healthineers.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version